Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Scilex Holding Company is a commercial-stage pharmaceutical company focused on non-opioid pain management products, primarily marketing ZTlido (lidocaine topical patch 1.8%) for acute pain and SP-102 (10 mg dexamethasone sodium phosphate viscous gel) for lumbar radicular pain. The company operates in a highly competitive specialty pharmaceutical market with significant cash burn, negative operating margins, and critical liquidity constraints reflected in a 0.05 current ratio, positioning it as a high-risk turnaround candidate dependent on successful commercialization and capital access.
Scilex generates revenue through direct sales and distribution partnerships for FDA-approved non-opioid pain management products targeting the $20+ billion US pain management market. The company focuses on differentiated delivery mechanisms (topical patches, viscous gel injections) that provide localized pain relief without systemic opioid exposure. Gross margins of 70.5% reflect typical specialty pharma economics with third-party manufacturing, but the company faces substantial commercialization costs, resulting in -147% operating margins. Pricing power depends on formulary access, reimbursement coverage from commercial and government payers, and clinical differentiation versus generic alternatives and competitive non-opioid therapies.
ZTlido prescription volume trends and market share versus competing lidocaine patches (Lidoderm generics, Ztlido competitors)
SP-102 commercial launch execution, formulary wins, and quarterly sales ramp following recent FDA approval
Capital structure events - equity raises, debt refinancing, or strategic partnerships given critical liquidity position
Clinical trial readouts or regulatory updates for pipeline assets including SEMDEXA
Quarterly cash burn rate and runway visibility given negative operating cash flow
Intense competition in non-opioid pain management from established generics (lidocaine patches under $50/month), newer modalities (neuromodulation devices, biologics), and well-capitalized competitors with broader product portfolios
Reimbursement pressure from PBMs and government payers increasingly scrutinizing specialty drug pricing, with potential for formulary exclusions or step-therapy requirements that disadvantage newer branded products
Regulatory pathway uncertainty for pipeline assets, particularly SEMDEXA, where FDA requirements for epidural steroids have evolved following safety concerns in the broader category
ZTlido faces direct competition from generic lidocaine patches and OTC alternatives at significantly lower price points, limiting market share expansion despite differentiated 1.8% formulation
SP-102 competes with established corticosteroid injections (generic dexamethasone, methylprednisolone) and newer targeted therapies, requiring substantial clinical evidence and KOL adoption to justify premium pricing
Large pharmaceutical companies (Pfizer, Johnson & Johnson, AbbVie) with pain management franchises can leverage superior sales forces, payer relationships, and R&D resources to outcompete smaller specialty players
Critical liquidity crisis indicated by 0.05 current ratio and negative operating cash flow, suggesting fewer than 1-2 quarters of cash runway without immediate financing
Negative tangible book value (-0.5x price/book) and 181% ROE driven by negative equity base, indicating accumulated deficits exceed assets and potential balance sheet insolvency without restructuring
High dilution risk from equity raises needed to fund operations, with 56.7% EPS growth likely reflecting share count changes rather than operational improvement given negative net margins
moderate - Healthcare spending, particularly for pain management, shows relative resilience during economic downturns as medical needs persist. However, elective procedures for chronic pain (where SP-102 targets lumbar radicular pain) can see volume pressure during recessions as patients delay non-urgent treatments. Commercial insurance coverage and patient out-of-pocket costs become more sensitive during economic stress, potentially impacting prescription fill rates. The company's specialty pharma focus provides some insulation versus discretionary healthcare, but not complete immunity to GDP fluctuations.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting SCLX's negative earnings profile; (2) Increased cost of capital makes future equity raises more dilutive and debt financing more expensive, critical given the 0.05 current ratio and negative operating cash flow; (3) Risk-off sentiment during rate hiking cycles reduces investor appetite for speculative biotech/pharma names. The company's -$0.0B free cash flow makes it highly dependent on capital markets access, amplifying rate sensitivity.
Moderate exposure through multiple channels: (1) The company's own credit access is critical given liquidity constraints - tightening credit conditions could impair ability to secure working capital facilities or convertible debt; (2) Hospital and pharmacy credit quality affects receivables collection, though less material than for device companies; (3) Payer mix matters as government programs (Medicare/Medicaid) provide more stable reimbursement than commercial insurers during credit stress. The negative -0.38 debt/equity ratio suggests complex capital structure potentially involving warrants, convertibles, or off-balance sheet obligations.
Speculative growth/turnaround investors willing to accept extreme volatility and binary outcomes. The -52.9% three-month return, negative operating margins, and critical liquidity position attract distressed/special situations funds, biotech-focused hedge funds with high risk tolerance, and retail momentum traders. Not suitable for value investors (negative book value), income investors (no dividends, negative cash flow), or risk-averse institutions. The 28% FCF yield appears anomalous given negative operating cash flow and likely reflects market cap compression rather than actual cash generation.
high - The stock exhibits extreme volatility driven by binary catalysts (financing announcements, clinical/regulatory updates, quarterly cash burn reports), thin trading liquidity typical of micro-cap biotechs, and existential balance sheet risks. The -54.9% six-month decline indicates sustained selling pressure, while the small $100M market cap amplifies price swings from modest order flow. Investors should expect continued 20-40% monthly volatility ranges until the company establishes sustainable cash flow or secures strategic financing.
